- Home
- SRAD vs STVN Comparison
SRAD vs STVN Comparison
Compare SRAD & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRAD
- STVN
- Stock Information
- Founded
- SRAD 2001
- STVN 1949
- Country
- SRAD Switzerland
- STVN Italy
- Employees
- SRAD N/A
- STVN N/A
- Industry
- SRAD Computer Software: Programming Data Processing
- STVN Containers/Packaging
- Sector
- SRAD Technology
- STVN Consumer Discretionary
- Exchange
- SRAD Nasdaq
- STVN Nasdaq
- Market Cap
- SRAD 5.2B
- STVN 6.2B
- IPO Year
- SRAD 2021
- STVN 2021
- Fundamental
- Price
- SRAD $16.94
- STVN $19.02
- Analyst Decision
- SRAD Strong Buy
- STVN Buy
- Analyst Count
- SRAD 9
- STVN 3
- Target Price
- SRAD $15.56
- STVN $29.33
- AVG Volume (30 Days)
- SRAD 861.9K
- STVN 614.1K
- Earning Date
- SRAD 11-07-2024
- STVN 11-05-2024
- Dividend Yield
- SRAD N/A
- STVN 0.30%
- EPS Growth
- SRAD N/A
- STVN N/A
- EPS
- SRAD 0.20
- STVN 0.48
- Revenue
- SRAD $1,173,401,739.00
- STVN $1,220,254,294.00
- Revenue This Year
- SRAD $25.68
- STVN $3.01
- Revenue Next Year
- SRAD $13.33
- STVN $7.78
- P/E Ratio
- SRAD $83.14
- STVN $40.04
- Revenue Growth
- SRAD 26.55
- STVN 3.53
- 52 Week Low
- SRAD $9.17
- STVN $16.56
- 52 Week High
- SRAD $17.52
- STVN $34.73
- Technical
- Relative Strength Index (RSI)
- SRAD 80.20
- STVN 43.43
- Support Level
- SRAD $12.26
- STVN $17.12
- Resistance Level
- SRAD $17.52
- STVN $22.07
- Average True Range (ATR)
- SRAD 0.60
- STVN 1.37
- MACD
- SRAD 0.46
- STVN -0.05
- Stochastic Oscillator
- SRAD 88.97
- STVN 21.48
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.